Ampio premature ejaculation drug shows more promise as firm's initial focus is outside US
This article was originally published in Scrip
Executive Summary
Ampio Pharmaceuticals, which "repurposes" old drugs and revealed earlier this month its first partner for Zertane, its formulation of tramadol for premature ejaculation (PE), has announced positive results from a 12-week open-label extension study. The open-label study was performed at the conclusion of Phase III trials.